Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
Disablement of cell death programs in cancer cells contributes to drug resistance and in some cases has been associated with altered translational control. As eukaryotic translation initiation factor 4E (eIF4E) cooperates with c-Myc during lymphomagenesis, induces drug resistance, and is a genetic modifier of the rapamycin response, we have investigated the effect of dysregulation of the ribosome recruitment phase of translation initiation on tumor progression and chemosensitivity. eIF4E is a subunit of eIF4F, a complex that stimulates ribosome recruitment during translation initiation by delivering the DEAD-box RNA helicase eIF4A to the 5' end of mRNAs. eIF4A is thought to prepare a ribosome landing pad on mRNA templates for incoming 40S ribosomes (and associated factors). Using small molecule screening, we found that cyclopenta[b]benzofuran flavaglines, a class of natural products, modulate eIF4A activity and inhibit translation initiation. One member of this class of compounds, silvestrol, was able to enhance chemosensitivity in a mouse lymphoma model in which carcinogenesis is driven by phosphatase and tensin homolog (PTEN) inactivation or elevated eIF4E levels. These results establish that targeting translation initiation can restore drug sensitivity in vivo and provide an approach to modulating chemosensitivity.
Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Marie-Eve
ME
Bordeleau
Francis
F
Robert
Baudouin
B
Gerard
Lisa
L
Lindqvist
Samuel M H
SM
Chen
Hans-Guido
HG
Wendel
Brigitte
B
Brem
Harald
H
Greger
Scott W
SW
Lowe
John A
JA
Porco
Jerry
J
Pelletier
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001572:Benzofurans / Q000494:pharmacology*; D002460:Cell Line; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004357:Drug Synergism; D039601:Eukaryotic Initiation Factor-4A / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D039561:Eukaryotic Initiation Factor-4E / Q000378:metabolism; D005260:Female; D006367:HeLa Cells; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D051059:PTEN Phosphohydrolase / Q000235:genetics; D010442:Peptide Chain Initiation, Translational / Q000187:drug effects*; D000071137:Poly (ADP-Ribose) Polymerase-1; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D011132:Polyribosomes / Q000187:drug effects / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D020123:Sirolimus / Q000494:pharmacology; D019284:Thapsigargin / Q000494:pharmacology; D014315:Triterpenes / Q000494:pharmacology*
C514038:1-O-formylrocagloic acid; D001572:Benzofurans; D039561:Eukaryotic Initiation Factor-4E; D014315:Triterpenes; C489897:silvestrol; D019284:Thapsigargin; D004317:Doxorubicin; C499321:Parp1 protein, mouse; D000071137:Poly (ADP-Ribose) Polymerase-1; D011065:Poly(ADP-ribose) Polymerases; D051057:Proto-Oncogene Proteins c-akt; D039601:Eukaryotic Initiation Factor-4A; D051059:PTEN Phosphohydrolase; C487757:Pten protein, mouse; D020123:Sirolimus